Not yet recruitingInterventionalPhase 1Phase 2Last updated Aug 14, 2026

Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.

A Phase I/II Open-Label Clinical Study of Autologous Tumor Infiltrating Lymphocyte Infusion (GT201) in the Treatment of Advanced Solid Tumors

Overview

ClinicalTrials.gov ID: NCT07766317
Lead Sponsor: Gritbio Medicine, Inc.INDUSTRY
Brief Summary: This is a multicenter, single-arm phase 1/2 clinical trial to evaluate the safety and tolerability of GT201 as a monotherapy or in combination with anti-PD-1 therapy in patients with advanced solid tumors, and to evaluate the efficacy of this therapy.
Study Type: Interventional

Status

Study Record Dates

NCT05729399Terminated

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

NCT05430360Terminated

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors

NCT06519669Terminated

Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer

NCT06144671Recruiting

GT201 Injection For The Treatment Of Advanced Solid Tumors

NCT05724732Unknown status

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

NCT06834542Terminated

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors